Reviva Pharmaceuticals Stock (NASDAQ: RVPH)

Reviva Pharmaceuticals (NASDAQ:RVPH) Stock

Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

Amazon, Crowdstrike, Autodesk, Dell, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

CANG

CELC

DBGI

EVGO

GRYP

LAES

MAMA

MITK

Merrill Lynch & Strategic Return Notes for Select 10 Index

NAYA

OPTX

PSBD

PTPI

RVPH

SEDG

SIDU

TNXP

WBUY

Why Mitek Systems Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket

Analyst Color

Biotech

Health Care

Analyst Ratings

General

The FDA&#39;s approval of Bristol Myers Squibb&#39;s Cobenfy for schizophrenia opens doors for Reviva&#39;s brilaroxazine, a multi-receptor antipsychotic.

Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst

Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) shares are surging after the company released topline results of its pivotal Phase 3 RECOVER trial evaluating brilaroxazine, a serotonin-dopamine signaling modulator in 

Analyst Assessment On Reviva Pharmaceuticals&#39; Positive Schizophrenia Trial Data - Sees More Than 200% Upside In Stock

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals Holdings Inc

Reviva Pharmaceuticals Holdings, Inc. - Warrants

Mizuho analyst Ben Chaiken maintains Marriott Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) with a Outperform and raises the price target from $117 to $120.

Price Target

Mizuho Maintains Outperform on Marriott Vacations, Raises Price Target to $120

GTBP

GT Biopharma  Files Request For Withdrawal With SEC  With Respect To Withdrawal Of Form S-1 Registration Statement, Filed On Dec. 23

Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 700 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $148.546 million which beat the analyst consensus estimate of $146.380 million by 1.48 percent. This is a 15.92 percent increase over sales of $128.145 million the same period last year.

Earnings

Earnings Beats

XMTR

Xometry Q4 2024 Adj. EPS $0.06 Beats $0.03 Estimate, Sales $148.546M Beat $146.380M Estimate

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) with a Buy and maintains $15 price target.

Reiteration

TBPH

HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $15 Price Target

Citigroup analyst Asiya Merchant maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Buy and raises the price target from $60.45 to $64.

Citigroup Maintains Buy on Western Digital, Raises Price Target to $64

Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.32) by 3.13 percent. This is a 22.5 percent increase over losses of $(0.40) per share from the same period last year.

FULC

Fulcrum Therapeutics Q4 GAAP EPS $(0.31) Beats $(0.32) Estimate

DOCN

DigitalOcean Holdings Q4 2024 Adj. EPS $0.49 Beats $0.34 Estimate, Sales $204.925M Beat $200.507M Estimate

Stantec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STN#NYSE">STN</a>) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.69 by 14.49 percent. This is a 31.67 percent increase over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $1.06 billion which beat the analyst consensus estimate of $1.01 billion by 4.65 percent. This is a 15.81 percent increase over sales of $912.70 million the same period last year.

Stantec Q4 Adj $0.79 Beats $0.69 Estimate, Sales $1.06B Beat $1.01B Estimate

Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.15 by 6.67 percent. This is a 75 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $1.02 billion which beat the analyst consensus estimate of $1.01 billion by 0.98 percent. This is a 1.45 percent decrease over sales of $1.03 billion the same period last year.

ELAN

Elanco Animal Health Q4 2024 Adj EPS $0.14 Misses $0.15 Estimate, Sales $1.02B Beat $1.01B Estimate

WIIM

RDHL

RedHill shares are trading higher after the company announced an exclusive licensing agreement with Hyloris Pharmaceuticals for RHB-102, including an upfront payment and up to $60 million in potential milestones.

<ul>
<li>Food Processing to be a Fast-Growing and Nimble Standalone Business with Best-in-Class Technologies for Industrial Protein, Bakery, and Snack Processors</li>
<li>Middleby RemainCo Well-Positioned to Drive Sustainable Growth and Margin Expansion Through Innovation Leadership and Differentiated Go-To-Market Capabilities in Commercial Foodservice and Residential Kitchens</li>
<li>Separation of Food Processing Expected to be Achieved Through Tax-Free Spin-Off and be Completed Early 2026</li>
<li>Company Separately Announces Q4 and Full-Year 2024 Financial Results and Appointment of Independent Directors to its Board</li>
</ul>

MIDD

Middleby To Spin Off Food Processing Unit, Forming Independent Food Processing And Kitchen Equipment Leaders

RedHill Enters Exclusive Development And Commercialization Licensing Agreement With Hyloris Pharmaceuticals For RHB-102; Hyloris Will Pay Co. Upfront Payment And Up To $60M In Potential Milestones

For the full year 2025, the Company expects GAAP revenue of approximately $1.0 billion, representing revenue growth of approximately 5% year-over-year. The Company expects Adjusted Gross Profit Margin to be in the range of 47.0% to 47.5%. The Company expects Adjusted EBITDA to be in the range of $225 million to $235 million and Adjusted Diluted EPS to be in the range of $3.35 to $3.55. The Company's guidance assumes no significant changes in foreign exchange rates.
For the first quarter of 2025, the Company expects GAAP revenue of approximately $232 million to $236 million. The Company expects Adjusted Gross Profit Margin to be in the range of 46.0% to 46.5%. The Company expects Adjusted EBITDA to be in the range of $48 million to $51 million and Adjusted Diluted EPS to be in the range of $0.63 to $0.71. The Company's guidance assumes no significant changes in foreign exchange rates.

Guidance

NOVT

Novanta Expects Q1 Revenue Of $232M-$236M Vs $244.89M Est, Adj EPS Of $0.63-$0.71 Vs $0.78 Est

AdaptHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.27 by 25.93 percent. The company reported quarterly sales of $856.65 million which beat the analyst consensus estimate of $829.19 million by 3.31 percent. This is a 0.18 percent decrease over sales of $858.23 million the same period last year.

AHCO

AdaptHealth Q4 2024 GAAP EPS $0.34 Beats $0.27 Estimate, Sales $856.65M Beat $829.19M Estimate

Delek US Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DK#NYSE">DK</a>) reported quarterly losses of $(2.54) per share which beat the analyst consensus estimate of $(2.81) by 9.61 percent. This is a 73.97 percent decrease over losses of $(1.46) per share from the same period last year. The company reported quarterly sales of $2.37 billion which missed the analyst consensus estimate of $2.58 billion by 7.84 percent. This is a 41.38 percent decrease over sales of $4.05 billion the same period last year.

Earnings Misses

Delek US Hldgs Q4 2024 Adj EPS $(2.54) Beats $(2.81) Estimate, Sales $2.37B Miss $2.58B Estimate

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) sees FY2025 sales of $818.000 million-$826.000 million vs $847.01 million analyst estimate.

OFIX

Orthofix Medical Sees FY2025 Sales $818.000M-$826.000M vs $847.01M Est

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.05) by 140 percent. This is a 103.39 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $215.66 million which beat the analyst consensus estimate of $212.71 million by 1.38 percent. This is a 7.61 percent increase over sales of $200.41 million the same period last year.

Orthofix Medical Q4 Adj $0.02 Beats $(0.05) Estimate, Sales $215.66M Beat $212.71M Estimate

Sealed Air Sees FY25 Revenue Of $5.100B - $5.500B Vs. $5.4B Est; Adj EPS Of $2.90 - $3.30 Vs. $3.12 Est.

2025 Financial Guidance: We expect revenue growth to be in the range of 15% to 17%. In addition, we anticipate gross margin to be in the range of 73% - 75%. This includes one-time costs, mainly related to the anticipated BLA approval, impacting gross margin by approximately 1%. Additionally, we expect to be net cash flow positive for the full year.

AXGN

Axogen Expects 2025 Revenue Growth Of 15%-17%, The Company Expects Gross Margin Of 73%-75%

Guidance for Fiscal Year 2025
The Company is providing its financial guidance for fiscal year 2025, as follows:
<ul>
<li>Net revenue of $3.22 billion to $3.36 billion;</li>
<li>Adjusted EBITDA of $670 million to $710 million;</li>
<li>Free cash flow of $180 million to $220 million</li>
</ul>

AdaptHealth Sees FY2025 Sales $3.220B-$3.360B vs $3.33B Est

Press Releases

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia

Comments

Reviva Pharmaceuticals

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga